Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BFRIW | US
0
0%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
20/03/2026
0.06
0.06
0.06
0.06
Biofrontera Inc. a biopharmaceutical company develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn Massachusetts.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
506.6%1 month
487.3%3 months
393.1%6 months
316.7%-
-
-
0.13
0.07
-
-
-
-18.32M
-
-
-
-64.69
-
34.00
-149.41
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.03
Range3M
0.05
Rel. volume
4.87
Price X volume
1.05K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sunshine Biopharma Inc. Warrant | SBFMW | Drug Manufacturers-Specialty & Generic | 0.0851 | 0 | 0.00% | n/a | 2.46% |
| CURE Pharmaceutical Holding Corp | CURR | Drug Manufacturers-Specialty & Generic | 2.65 | 0 | 3.92% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 12.84 | 0 | -0.08% | n/a |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | - | - |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | - | 13.15 | - |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 393.15 | - | Riskier |
| Debt to Equity | 0.13 | -1.88 | Expensive |
| Debt to Assets | 0.07 | 0.48 | Cheaper |
| Market Cap | - | - | - |